Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
38.50
+0.44 (1.16%)
Jun 2, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Revenue
Hangzhou Biotest Biotech had revenue of 89.38M CNY in the quarter ending March 31, 2026, with 1.70% growth. This brings the company's revenue in the last twelve months to 449.50M, down -12.15% year-over-year. In the year 2025, Hangzhou Biotest Biotech had annual revenue of 448.01M, down -19.91%.
Revenue (ttm)
449.50M
Revenue Growth
-12.15%
P/S Ratio
12.53
Revenue / Employee
733.28K
Employees
613
Market Cap
5.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 448.01M | -111.39M | -19.91% |
| Dec 31, 2024 | 559.40M | 117.29M | 26.53% |
| Dec 31, 2023 | 442.11M | -1.46B | -76.75% |
| Dec 31, 2022 | 1.90B | 83.07M | 4.57% |
| Dec 31, 2021 | 1.82B | 952.70M | 110.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.95B |
| Novogene | 2.26B |
| Shenzhen Weiguang Biological Products | 1.26B |
| Chengdu Kanghua Biological Products | 1.20B |
| Wuhan Keqian Biology Co.,Ltd | 932.09M |
| Beijing Konruns Pharmaceutical | 917.99M |
| R&G PharmaStudies | 896.26M |
| Jiangsu Aidea Pharmaceutical Group | 699.33M |